News & Resources
Association between regional volume change and clinical change in Huntington’s disease HD-ISS Stage 2 and Stage 3 participants
For HD-ISS Stage 2 and Stage 3 participants, whole-brain volume shows significant association with clinical change for all four clinical variables examined here. For caudate and putamen volume, the association depended on the clinical variable. Our results provide further evidence on the use of volume change as a surrogate endpoint.
A Deep Learning Framework For Clinical Trial Enrichment in Alzheimer’s Disease
The selection of participants at risk of cognitive decline in clinical trials, known as trial enrichment, increases the probability of trial success. It is estimated that by 2050, 153 million people worldwide will be living with a type of dementia. Hence, innovative trial recruitment strategies are necessary to accelerate treatment development.
Comparison of amyloid positivity and global cortical SUVR between black and white non-Hispanic participants in the GAP Bio-Hermes study
Summary: This poster shows our further investigation on the amyloid PET differences between Black and White participants in the GAP Bio-Hermes study and to better understand the relationship between Aβ+ status from visual read and quantitative SUVR.
A convolutional neural network-based framework for imaging biomarkers in MS - white matter hyperintensity & brain region volumes
Summary: We developed and validated scalable and robust methods for automated volumetric analysis of brain white matter hyperintensities (T2 lesions) and regions of interest in multiple sclerosis.
The impact of diversity on Alzheimer's disease clinical trial design
Lammert Albers, Chief Commercial Officer of the Global Alzheimer's Platform Foundation talks with John Dwyer, President of the foundation, and our Chief Scientific Officer, Robin Wolz about the impact of this study diversity on current and future research and the opportunities at hand at the upcoming CTAD Clinical Trials on Alzheimer's Disease 2023 conference in Boston.
Automated VMAT2 [18F] AV-133 PET analysis in Parkinson's disease
We discuss our latest work to evaluate a fully automated image analysis pipeline to process vesicular monoamine transporters type 2 (VMAT2) [18F]AV-133 tracer positron emission tomography (PET) images, by comparison with a methodology requiring manual intervention.
33-40 of 165 results